Pharmaceutical Costs for Neurologic Disorders

Date/Time: Tuesday, October 23, 2018 - 11:00 AM to 12:00 PM
Type: Interactive Lunch Workshop
Room: Regency V

Session Overview

Chair: Lindsey De Lott
Co-Chair: Kevin Kerber

Prescription drug spending in the US far exceeds that in all other countries, with per capita spending of $858 compared to $400 for 19 other industrialized countries. Over the last 5 years a particularly sharp increase in drug spending has occured. About 1 in 4 people in the US who take prescription drugs report difficulty affording them. Neurologists comprise about 1% of providers in the US and 5% ($5billion) of total Medicare drug payments - third highest of all specialties. Issues related to drug cost include substantial rise in cost of old medicines (e.g., glatiramer acetate) and extremely high costs for new medicines (e.g., deflazacort, nusinersen). This symposium will present the current status, trends, and emerging issues regarding US drug prices for neurological disorders.

Objectives

  • Describe the landscape of drug prices in neurological disease.
    Differentiate trends and reasons for drug prices in multiple sclerosis.
    Describe the Orphan Drug Act, prices, and impact of new orphan drugs.
    Describe industry approaches to pricing.